Lux Capital

Lux Capital is a prominent venture capital firm renowned for its focus on "frontier technology" and "deep tech" investments. With offices in New York and Menlo Park, the firm has carved out a niche by backing audacious, often counter-conventional, science and technology ventures at their nascent stages. Their investment thesis centers on identifying and nurturing companies that are pushing the boundaries of what's possible, spanning sectors such as artificial intelligence, robotics, advanced materials, space exploration, and biotechnology. Lux Capital prides itself on its long-term vision, supporting founders who are tackling complex, foundational problems with disruptive solutions.

The firm primarily targets seed and early-stage companies, typically participating in Series A rounds, though they maintain the capacity for follow-on investments in later stages. Lux Capital is known for writing substantial initial checks, with typical first investments ranging from $5 million to $15 million. This significant early capital allows their portfolio companies to build robust foundations and accelerate their research and development efforts. Their willingness to commit considerable resources to unproven, high-risk, high-reward ventures underscores their unique approach in the venture landscape.

Lux Capital manages a substantial pool of capital, overseeing over $5 billion in assets across a dozen dedicated funds. This considerable financial backing enables them to provide sustained support to their portfolio companies as they scale. A testament to their continued growth and commitment to the deep tech sector is their latest fund, Lux Capital VII, which closed at an impressive $1.5 billion in 2022. This large fund size further solidifies their position as a leading investor in groundbreaking scientific and technological innovations, allowing them to make impactful investments in capital-intensive sectors. Their portfolio includes notable successes like Auris Health, acquired by Johnson & Johnson for $5.75 billion, and Recursion Pharmaceuticals, which went public.